Skip to main content

Table 4 Hazard ratiosa according to tertiles of serum 25(OH)D and chemotherapy

From: Serum 25-hydroxyvitamin D and postmenopausal breast cancer survival: a prospective patient cohort study

  Serum 25(OH)D
  Continuous Categorized
  per 10 nmol/L decrement < 35 nmol/L 35-55 nmol/L ≥ 55 nmol/L
Outcome No.
(events)
HR 95% CI P trend b No.
(events)
HR 95% CI No.
(events)
HR 95% CI No.
(events)
HR 95% CI
Overall mortality              
   All 1,265 (174) 1.08 1.00 to 1.17 0.07 422 (82) 1.55 1.00 to 2.39 397 (44) 0.72 0.45 to 1.17 446 (48) 1.00 -
   No/before CTc 911 (99) 1.15 1.03 to 1.27 0.02 292 (51) 2.17 1.18 to 3.99 276 (20) 1.00 0.51 to 1.96 343 (28) 1.00 -
   After CTd 339 (71) 0.91 0.75 to 1.08 0.27 121 (29) 0.82 0.35 to 1.95 117 (22) 0.59 0.24 to 1.44 101 (20) 1.00 -
Distant disease              
   All 1,074 (135) 1.14 1.05 to 1.24 0.006 338 (63) 2.09 1.29 to 3.41 342 (37) 1.16 0.70 to 1.94 394 (35) 1.00 -
   No/before CTc 844 (103) 1.17 1.06 to 1.29 0.005 259 (50) 2.41 1.37 to 4.22 263 (26) 1.07 0.59 to 1.94 322 (27) 1.00 -
   After CTd 221 (32) 1.12 0.85 to 1.39 0.41 73 (13) 1.79 0.35 to 9.00 78 (11) 0.84 0.14 to 4.97 70 (8) 1.00 -
  1. Note: 18 and 9 participants, respectively, had missing data on chemotherapy and were excluded from the stratified analyses.
  2. 25(OH)D, 25-hydroxyvitamin D; CI, confidence interval; CT, chemotherapy; HR, hazard ratio.
  3. a Stratified by age at diagnosis and season, adjusted for tumor size, nodal status, metastases, tumor grade, estrogen/progesterone receptor status, diabetes, mode of detection
  4. b Calculated by using serum 25(OH)D as a continuous variable.
  5. c No chemotherapy or blood collection before start chemotherapy.
  6. d Blood collection after start chemotherapy.
  7. Pinteraction = 0.06 and 0.49 for overall mortality and distant disease, respectively.